Back to Blog
Regulatory April 15, 2026

FDA Peptide Shake-Up: What Kennedy's 12-Peptide Announcement Actually Means

Secretary Kennedy says FDA will remove 12 peptides from Category 2 and begin PCAC review in July 2026. Here is what the official FDA notice confirms, what is scheduled later, and what still is not clear.

Secretary Kennedy posted on April 15, 2026 that FDA will remove a group of peptides from Category 2 and begin bringing them to the Pharmacy Compounding Advisory Committee, or PCAC, starting in July.

That is a meaningful development.

It is also the kind of announcement that can get oversimplified fast.

The headline version is easy to understand:

  • a group of widely discussed peptides is no longer being framed the same way under the Category 2 safety-risk bucket
  • FDA says outside experts will now evaluate the substances through the PCAC process
  • the first public meeting is already scheduled for late July 2026

But if you read the official notice, there is an important nuance:

The public FDA meeting notice currently confirms the first July agenda items, not the full 12-substance list from the X post.

Kennedy’s announcement

The post from Secretary Kennedy said FDA will remove the following substances from Category 2 and bring them to PCAC beginning in July:

  • BPC-157
  • Thymosin beta-4 fragment (LKKTETQ)
  • Epitalon
  • GHK-Cu (injectable)
  • MOTS-c
  • DSIP (Emideltide)
  • Dihexa Acetate
  • Ibutamoren Mesylate
  • Melanotan II
  • KPV
  • Semax (heptapeptide)
  • Cathelicidin LL-37

If that post is directionally accurate, it would be a major regulatory shift for the peptide-compounding conversation.

But an X post is not the same thing as a final FDA action document, a final rule, or a final inclusion decision on the 503A bulks list.

That is why the official meeting notice matters.

What the official July 2026 FDA notice confirms

FDA has already published a public advisory committee notice for a Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026.

According to the FDA notice and public inspection document:

  • the meeting will be held July 23, 2026 from 8:00 a.m. to 4:30 p.m. ET
  • and July 24, 2026 from 8:00 a.m. to 3:50 p.m. ET
  • at FDA White Oak Campus, 10903 New Hampshire Ave., Building 31, Room 1503, Silver Spring, Maryland
  • with a public remote participation option

The notice also sets up the public comment process:

  • docket number: FDA-2025-N-6895
  • comments close: July 22, 2026
  • comments received by July 9, 2026 will be provided to the Committee
  • requests for oral presentations are due by June 30, 2026

Which peptides are actually on the July agenda

This is where things get more specific.

The official July 23-24 FDA agenda currently identifies these substance groups for discussion:

July 23, 2026

  • BPC-157-related bulk drug substances
  • KPV-related bulk drug substances
  • TB-500-related bulk drug substances
  • MOTs-C-related bulk drug substances

July 24, 2026

  • Emideltide-related bulk drug substances, also referred to as DSIP
  • Semax-related bulk drug substances
  • Epitalon-related bulk drug substances

The notice also lists the use cases FDA reviewed for those discussions:

  • BPC-157: ulcerative colitis
  • KPV: wound healing and inflammatory conditions
  • TB-500: wound healing
  • MOTs-C: obesity and osteoporosis
  • Emideltide / DSIP: opioid withdrawal, chronic insomnia, and narcolepsy
  • Semax: cerebral ischemia, migraine, and trigeminal neuralgia
  • Epitalon: insomnia

The part people should not miss

The July notice does not currently list all 12 substances mentioned in Kennedy’s post.

At least in the public materials available now, the following names from the X post are not listed in the July 23-24 agenda:

  • Thymosin beta-4 fragment (LKKTETQ)
  • GHK-Cu (injectable)
  • Dihexa Acetate
  • Ibutamoren Mesylate
  • Melanotan II
  • Cathelicidin LL-37

That does not necessarily mean they are excluded.

In fact, FDA already has a separate PCAC meeting page up for a later meeting before the end of February 2027 that lists:

  • Cathelicidin (LL-37)
  • GHK-Cu
  • Dihexa acetate
  • Melanotan II
  • PEG-MGF

That is important because it suggests at least some of the names missing from the July 2026 agenda are not missing from the process altogether. They appear to be moving on a later advisory-committee timetable instead.

It may simply mean:

  • they are being handled in a later meeting
  • they are part of a different procedural track
  • or more detail has not been published yet in the formal meeting materials

So based on the public FDA materials available right now, the clearest read is:

  • July 2026 is the first confirmed meeting for seven of the named peptide groups
  • a later FDA PCAC meeting is already signaled for at least four more related substances
  • Ibutamoren mesylate and Thymosin beta-4 fragment (LKKTETQ) are still not clearly placed on a public PCAC agenda page we can point to yet

That is a more precise picture than saying all 12 are already confirmed for the July 23-24 agenda.

What this does and does not mean yet

This looks like a real process change.

It does not mean all of these peptides suddenly have final cleared status for compounding, commercial sale, or broad regulated access overnight.

What it does appear to mean is:

  • FDA is moving at least some of these substances into a more formal advisory review track
  • independent experts at PCAC will evaluate them in public
  • nominators will have a chance to support the nominations
  • the public can comment before the meeting

That is much more concrete than rumor-cycle chatter, but it is still a process step, not the end of the process.

Why this matters for the peptide market

Kennedy’s post explicitly framed the old setup as something that pushed demand into a black market.

Whether people agree with that framing or not, the practical point is easy to understand:

When regulators create uncertainty around popular compounded substances, demand does not just disappear. It often shifts into less transparent channels.

That is one reason this meeting matters beyond policy insiders.

If FDA gives clearer guidance on these substances, it could affect:

  • compounding pharmacy behavior
  • prescriber confidence
  • patient expectations
  • peptide gray-market demand
  • how people talk about “regulated access” versus informal sourcing

The practical takeaway

The strongest version of the story right now is not:

FDA fully reopened access to 12 peptides.

The stronger and more defensible version is:

FDA appears to be changing course, and the first official public review step is now on the calendar for late July 2026.

That is still significant.

If you follow peptide regulation, compounding policy, or the gray-market spillover effects of FDA decisions, this is one of the more important dates on the calendar right now.

What to watch next

Here is the short list:

  • whether FDA publishes background materials two business days before the meeting
  • whether later notices add the rest of the substances named in Kennedy’s post
  • what nominators submit in support of these bulk drug substances
  • what the Committee says about clinical rationale, pharmacology, and safety
  • whether the July discussion changes the market’s assumptions around access

Sources